DBV Technologies S.A. (NASDAQ:DBVT) Short Interest Up 297.0% in October

DBV Technologies S.A. (NASDAQ:DBVT) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 1,330,000 shares, a growth of 297.0% from the October 15th total of 335,000 shares. Approximately 1.4% of the company’s shares are sold short. Based on an average daily trading volume, of 655,300 shares, the short-interest ratio is currently 2.0 days.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on DBVT shares. HC Wainwright lifted their price objective on shares of DBV Technologies from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th. StockNews.com initiated coverage on shares of DBV Technologies in a research report on Wednesday, November 6th. They set a “hold” rating on the stock. Finally, JMP Securities reiterated a “market outperform” rating and issued a $5.00 target price on shares of DBV Technologies in a report on Tuesday, September 24th.

DBV Technologies Trading Down 2.2 %

Shares of NASDAQ:DBVT traded down $0.01 during midday trading on Wednesday, hitting $0.62. The company had a trading volume of 72,309 shares, compared to its average volume of 231,567. DBV Technologies has a 12-month low of $0.50 and a 12-month high of $2.14. The company has a fifty day moving average of $0.74 and a two-hundred day moving average of $0.90.

Shares of DBV Technologies are going to reverse split on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 28th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. boosted its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the quarter. DBV Technologies comprises 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.